---
schema_version: "secwatch.filing_event.v1"
accession: "0000886744-25-000048"
form_type: "8-K"
ticker: "GERN"
cik: "0000886744"
company_name: "GERON CORP"
filed_at: "2025-08-06T23:59:59+00:00"
generated_at: "2026-05-17T20:16:48.544437+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.72
calibrated_materiality_score: 0.72
confidence: "high"
source: SEC EDGAR
---

# Geron Q2 net product revenue $49.0M, net loss narrows to $16.4M; new CEO named

## Summary
- Net product revenue of $49.0M from RYTELO in Q2 2025, up 24% QoQ; demand up 17% QoQ with over 1,000 ordering accounts.
- Net loss of $16.4M ($0.02/share) vs $67.4M loss ($0.10) in Q2 2024, driven by rising RYTELO sales and lower R&D costs.
- Phase 3 IMpactMF trial in myelofibrosis now over 95% enrolled; full enrollment expected by year-end 2025.
- Harout Semerjian appointed President and CEO; seasoned commercial hematology and oncology leader.
- FY2025 operating expense guidance maintained at $270M-285M; cash and securities $432.6M as of June 30.

## SEC filing metadata
- accession: 0000886744-25-000048
- form_type: 8-K
- ticker: GERN
- cik: 0000886744
- company_name: GERON CORP
- filed_at: 2025-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.72
- calibrated_materiality_score: 0.72
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/886744/000088674425000048/0000886744-25-000048-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/886744/000088674425000048/gern-20250806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000886744-25-000048
- JSON: https://secwatch.observer/filing/0000886744-25-000048.json
- Plain text: https://secwatch.observer/filing/0000886744-25-000048.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.